1

X4 Pharmaceuticals

#9925

Rank

$18.55M

Marketcap

US United States

Country

X4 Pharmaceuticals
Leadership team

Mr. Adam S. Mostafa (CFO, Treasurer & Assistant Sec.)

Dr. Paula Ragan Ph.D. (Founder, CEO, Pres, Sec. & Director)

Dr. Murray W. Stewart M.D. (Interim Chief Medical Officer & Director)

Products/ Services
Biotechnology, Clinical Trials, Health Care, Pharmaceutical, Therapeutics
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2014
Company Registration
SEC CIK number: 0001501697
Traded as
XFOR
Social Media
Overview
Location
Summary
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
History

X4 Pharmaceuticals was founded in 2015 by biotech veterans who wanted to make a difference in the lives of rare disease patients who lack effective therapies. The company has raised over $150 million in venture funding and is targeting clinical proof-of-concept with its lead program, X4P-001, in serious genetic immunodeficiencies.

Mission
X4 Pharmaceuticals’ mission is to develop an innovative pipeline of targeted medicines to make a meaningful difference in the lives of rare disease patients.
Vision
X4 Pharmaceuticals’ vision is to make a lasting difference in rare disease patients by developing transformative treatments to improve their lives.
Key Team

Dr. Richard Peters M.D., Ph.D. (Founder)

Dr. Keith T. Flaherty M.D. (Founder & Member of Corp. Advisory Board)

Dr. Renato T. Skerlj Ph.D. (Founder)

Dr. Mary DiBiase Ph.D. (Chief Operating Officer)

Dr. Arthur Taveras Ph.D. (Chief Scientific Officer)

Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. (VP of Investor Relations & Corp. Communications)

Dr. Robert David Arbeit (Sr. VP of Clinical Devel. and Translational Research)

Recognition and Awards
X4 Pharmaceuticals has been recognized by industry associations and has won multiple awards, such as FierceBiotech’s “Emerging Company of the Year” award and the “Innovation in Healthcare” award from the MassBio Awards.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

X4 Pharmaceuticals
Leadership team

Mr. Adam S. Mostafa (CFO, Treasurer & Assistant Sec.)

Dr. Paula Ragan Ph.D. (Founder, CEO, Pres, Sec. & Director)

Dr. Murray W. Stewart M.D. (Interim Chief Medical Officer & Director)

Products/ Services
Biotechnology, Clinical Trials, Health Care, Pharmaceutical, Therapeutics
Number of Employees
50 - 100
Headquarters
Cambridge, Massachusetts, United States
Established
2014
Company Registration
SEC CIK number: 0001501697
Traded as
XFOR
Social Media